BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023
December 06, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
December 05, 2023 08:00 ET
|
BioAtla, Inc.
Results from the Phase 2 BA3011 clinical non-small cell lung cancer (NSCLC) study demonstrated promising clinical benefits in heavily pre-treated non-squamous histology patients across key endpoints ...
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit
November 30, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
November 28, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
November 07, 2023 16:01 ET
|
BioAtla, Inc.
Observed additional clinical responses and FDA feedback supports path forward for CAB-AXL-ADC (BA3011) non-small cell lung cancer (NSCLC) registrational study; detailed interim Phase 2 data to be...
BioAtla to Participate in the Jefferies London Healthcare Conference
November 06, 2023 16:05 ET
|
BioAtla, Inc.
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award
October 12, 2023 07:30 ET
|
BioAtla, Inc.
SAN DIEGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023
October 10, 2023 07:30 ET
|
BioAtla, Inc.
Submitted abstract on CAB-AXL-ADC, BA3011, in non-small cell lung cancer (NSCLC) to the IASLC 2023 North America Conference on Lung Cancer; KOL event planned for December 4, 2023, following conclusion...
BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Participate in Upcoming Investor Conferences in August
August 03, 2023 16:01 ET
|
BioAtla, Inc.
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...